NCT00459186 - The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Metastatic, Androgen Independent Prostate CancerProstate Cancer

Interventions

DRUG

RAD001

Daily for two weeks

DRUG

Docetaxel

Infusion once per cycle

DRUG

Prednisone

Prednisone 5 mg by mouth twice daily

Trial Locations (5)

Massachusetts General Hospital, Boston

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

Beth Israel Deaconess Medical Center, Boston

Oregon Health Science University, Portland